2303:TWSEUnited Microelectronics Corp. Analysis
Data as of 2026-03-10 - not real-time
¥2,780.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
At the close of trading the stock sits at ¥2,780, just below the DCF‑derived fair value of ¥2,796, suggesting a modest upside. The 20‑day SMA (¥2,627) and 50‑day SMA (¥2,635) sit beneath the current price, reinforcing a short‑term uptrend. The MACD histogram (+18) is strongly positive with a bullish signal, and the RSI at 61 signals continued momentum without extreme overbought conditions. The price is testing the nearby resistance around ¥2,785 while remaining comfortably above the identified support at ¥2,502, offering a clear technical range. Volume has been stable, and the beta of 0.33 indicates limited sensitivity to broader market swings.
On the fundamentals side, Dawn Corp. posted a 22.8% revenue surge and boasts a robust gross margin of 66.7% and operating margin of 36.8%, underscoring a high‑quality earnings engine. With zero debt, a cash pile exceeding ¥1.56 bn and a low payout ratio of 17%, the dividend yield of 0.97% appears sustainable. The trailing P/E of 19.7 is well below the industry average of 36.9, positioning the stock as potentially undervalued relative to peers. The ROE of 15.8% and ROA of 12.3% reflect efficient capital deployment, while the free cash flow of ¥197 m supports ongoing growth initiatives. Although the 30‑day volatility 38% is elevated, the combination of strong cash generation, low leverage, and modest beta points to a relatively low overall risk profile.
On the fundamentals side, Dawn Corp. posted a 22.8% revenue surge and boasts a robust gross margin of 66.7% and operating margin of 36.8%, underscoring a high‑quality earnings engine. With zero debt, a cash pile exceeding ¥1.56 bn and a low payout ratio of 17%, the dividend yield of 0.97% appears sustainable. The trailing P/E of 19.7 is well below the industry average of 36.9, positioning the stock as potentially undervalued relative to peers. The ROE of 15.8% and ROA of 12.3% reflect efficient capital deployment, while the free cash flow of ¥197 m supports ongoing growth initiatives. Although the 30‑day volatility 38% is elevated, the combination of strong cash generation, low leverage, and modest beta points to a relatively low overall risk profile.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price testing resistance near ¥2,785
- bullish MACD histogram
- moderate 30‑day volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- valuation gap versus industry P/E
- strong cash generation and zero debt
- sustainable dividend with low payout ratio
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- high margins and double‑digit revenue growth
- robust balance sheet and free cash flow
- low beta and defensive profile in a tech niche
Key Metrics & Analysis
Financial Health
Revenue Growth22.80%
Profit Margin25.83%
P/E Ratio19.7
ROE15.77%
ROA12.29%
P/B Ratio3.0
Op. Cash Flow¥390.0M
Free Cash Flow¥197.1M
Industry P/E36.9
Technical Analysis
TrendNeutral
RSI61.0
Support¥2,502.00
Resistance¥2,785.00
MA 20¥2,627.55
MA 50¥2,634.74
MA 200¥2,463.15
MACDBullish
VolumeStable
Fear & Greed Index75.95
Valuation
Fair Value¥2,796.05
GradeUndervalued
TypeGrowth
Dividend Yield0.97%
Risk Assessment
Beta0.33
Volatility38.56%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.